Zuellig Pharma acquires Cialis and Alimta from Eli Lilly in certain ASEAN markets
Betsy Goodfellow | February 5, 2024 | News story | Business Services | Cialis, Eli Lilly, Pharmacy, Zuellig Pharma, acquisition
Zuellig Pharma has announced that it has completed the acquisition of two brands Cialis (Tadalafil) and Alita (Pemetrexed) from Eli Lilly for selected ASEAN markets, including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines and Thailand. The acquisition will take place via its wholly-owned subsidiary, Zanovex Pte.
Following the acquisition, it is intended that Zanovex will own the trademarks, marketing authorisations and license manufacturing information for both Alimta, a chemotherapy drug for the treatment of certain types of non-small cell lung cancer and malignant pleural mesothelioma, and Cialis, a men’s health product for the treatment of erectile dysfunction.
ZP Therapeutics, the commercial division of Zuellig Pharma, is planned to promote the brands in the relevant markets, having previously been responsible for the promotion and distribution these brands as part of a broader, long-term strategic partnership with Lilly in Brunei, Indonesia, Malaysia, Philippines and Thailand.
John Graham, group CEO at Zuellig Pharma, commented: “This acquisition marks a major milestone in the evolution of Zuellig Pharma to becoming an integrated healthcare solutions company. It demonstrates the increasing strength of ZP Therapeutics, which has extensive in-market expertise and capabilities in driving growth of healthcare products in Asia. We look forward to further expanding our commercial presence in the region through meaningful strategic partnerships with the world’s leading biopharma companies as we remain focused on our purpose of making healthcare more accessible to communities in Asia.”
Betsy Goodfellow
Related Content
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
Lilly’s drug for early Alzheimer’s shows promising results
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …
Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …
